A Phase 1 single ascending dose study of pure oral harmine in healthy volunteers
- 20 September 2024
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 38 (10) , 911-923
Abstract
Background: Harmine is a component of the hallucinogenic brew, Ayahuasca, which also contains the psychoactive compound, N, N-dimethyltryptamine. Whether pharmaceutical-grade harmine hydrochloride (HCl) has psychoactive effects, the doses at which these might occur, and the dose-response relationship to side effects and safety in humans are unknown. Methods: We conducted a Phase 1, open-label single ascending dose trial in healthy adults with normal body mass index and no prior psychiatric illness. The primary goal was to determine the maximum tolerated dose (MTD) of oral pharmaceutical-grade harmine HCl and to characterize safety and tolerability. A secondary goal was to ascertain whether any oral dose has psychoactive effects. Results: Thirty-four adult participants, aged 18–55 years, were screened for study eligibility. Twenty-five participants met eligibility criteria and were randomized to a single dose of 100, 200, 300, or 500 mg of harmine HCl, respectively, using a continuous reassessment method. The most common adverse events (AEs) observed were gastrointestinal and/or neurological, dose-related, and of mild to moderate severity. The MTD was determined to be between 100 and 200 mg and is weight-based, with 90% of those participants receiving >2.7 mg/kg experiencing a dose-limiting toxicity. No serious AEs of harmine HCl were identified. Conclusions: Harmine HCl can be orally administered to healthy participants in doses 2.7 mg/kg are associated with vomiting, drowsiness, and limited psychoactivity. This study is the first to systematically characterize the psychoactive effects of pharmaceutical quality harmine in healthy participants.Keywords
Funding Information
- National Institute of Diabetes and Digestive and Kidney Diseases (P30 DK020541)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK105015)
- National Institute of Diabetes and Digestive and Kidney Diseases (R01 DK128242)
This publication has 33 references indexed in Scilit:
- Ritual drug use during Inca human sacrifices on Ampato mountain (Peru): Results of a toxicological analysisJournal of Archaeological Science: Reports, 2022
- Pharmacological effects of harmine and its derivatives: a reviewArchives of Pharmacal Research, 2020
- Rapid antidepressant effects of the psychedelic ayahuasca in treatment-resistant depression: a randomized placebo-controlled trialPsychological Medicine, 2018
- Banisteriopsis caapi , a Forgotten Potential Therapy for Parkinson's Disease?Movement Disorders Clinical Practice, 2015
- Developments in harmine pharmacology — Implications for ayahuasca use and drug-dependence treatmentProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2012
- A case of β-carboline alkaloid intoxication following ingestion of Peganum harmala seed extractForensic Science International, 2008
- Sequenced treatment alternatives to relieve depression (STAR*D): rationale and designControlled Clinical Trials, 2004
- Subjective effects and tolerability of the South American psychoactive beverage Ayahuasca in healthy volunteersPsychopharmacology, 2001
- Pharmacokinetics of Hoasca alkaloids in healthy humansJournal of Ethnopharmacology, 1999
- Dose-Response Study of N,N-Dimethyltryptamine in HumansArchives of General Psychiatry, 1994